Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Eosinophilic Esophagitis (EoE) in Children as Young as 1 Year Old
20 sept. 2024 07h45 HE
|
Regeneron Pharmaceuticals, Inc.
Recommendation based on a Phase 3 trial showing a significantly greater proportion of children on Dupixent achieved histological remission compared to placebo, consistent with improvements seen in...
Dupixent® (dupilumab) Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esophagitis Published in the New England Journal of Medicine
26 juin 2024 17h30 HE
|
Regeneron Pharmaceuticals, Inc.
Majority of patients in this age group with eosinophilic esophagitis (EoE) receiving Dupixent achieved histologic remission, with improvements sustained up to one year Dupixent is the first and only...
Eosinophilic Esophagitis Market Size to Surpass US$ 941.8 million by 2031 - Growth Plus Reports
09 févr. 2024 05h30 HE
|
Growth Plus Reports
Pune, Feb. 09, 2024 (GLOBE NEWSWIRE) -- According to the latest report published by Growth Plus Reports, the global Eosinophilic Esophagitis Market is expected to clock US$ 941.8 million by 2031 and...
Dupixent® (dupilumab) FDA Approved as First and Only Treatment Indicated for Children Aged 1 Year and Older with Eosinophilic Esophagitis (EoE)
25 janv. 2024 14h29 HE
|
Regeneron Pharmaceuticals, Inc.
Approval based on Phase 3 EoE KIDS trial showing a greater proportion of children taking Dupixent achieved histological remission compared to placebo Expanded indication marks second disease for...
EsoCap reports positive topline results from ACESO Phase II trial investigating ESO-101 in eosinophilic esophagitis
05 déc. 2023 03h00 HE
|
EsoCap AG
ESO-101, EsoCap's lead product candidate, consists of a capsule with a rolled-up, thin mucoadhesive film with the anti-inflammatory corticosteroid, mometasone furoateEsoCap's novel targeted delivery...
Eosinophilic Esophagitis Market to Show Positive Growth by 2032, Examines DelveInsight | Key Companies - Bristol Myers Squibb, Ellodi, AstraZeneca, Kyowa Kirin, Allakos, Pfizer, Revolo, EsoCap AG, NexEos Diagnostics, Celgene
28 sept. 2023 13h00 HE
|
DelveInsight Business Research LLP
New York, USA, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Eosinophilic Esophagitis Market to Show Positive Growth by 2032, Examines DelveInsight | Key Companies - Bristol Myers Squibb, Ellodi, AstraZeneca,...
EsoCap completes patient recruitment in ACESO Phase II trial in eosinophilic esophagitis
05 sept. 2023 03h30 HE
|
EsoCap AG
EsoCap's novel targeted delivery platform is designed to increase mucosal contact time and drug deposition in the esophagus ESO-101, EsoCap's lead product candidate, consists of a capsule with a...
An Old Dog with a New Trick… Ellodi’s APT-1011 Promises EoE Patients a Convenient and Potent Treatment Alternative
15 août 2023 15h40 HE
|
Spherix Global Insights
Exton, Pennsylvania, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Since launching in May 2022, Sanofi/Regeneron’s Dupixent has been well received by gastroenterologists and allergists as an advancement for...
New Study on the Current State of Health Care for Eosinophilic Esophagitis
18 mai 2023 15h03 HE
|
Asthma and Allergy Foundation of America
Washington, D.C., May 18, 2023 (GLOBE NEWSWIRE) -- A groundbreaking report reveals challenges and barriers to timely diagnosis and effective treatment and management of a rare, but increasing...
Global Eosinophilic Esophagitis Market Size to grow USD 1927 Million by 2030 | CAGR of 34%; Spherical Insights & Consulting
31 oct. 2022 07h00 HE
|
SPHERICAL INSIGHTS LLP
New York, United States , Oct. 31, 2022 (GLOBE NEWSWIRE) -- According to a research report published by Spherical Insights & Consulting, the Global Eosinophilic Esophagitis Market Size to grow...